the UK and the EU overall in 1970-2012. We obtained estimates for 2017 by implementing a joinpoint regression model.
Introduction
Since official cancer mortality figures become available with a few years lag, we developed a method to predict mortality figures for all cancers and six major types of cancers in the European Union (EU) and the six largest countries of the Union [1, 2] . We were also able to validate our estimates [3] . Similar approaches have long been used in the USA [4] . Despite uncertainties inherent in any prediction, these are useful to understand patterns and trends in risk factor exposure for major cancers, and for public health planning.
In the present work, we predicted the number of cancer deaths and mortality rates for 2017 with specific focus on lung cancer, and its recent trends in the two sexes, various age groups and countries [5, 6] .
Materials and methods
This work updates the previous articles on European cancer mortality predictions, and it uses similar methods [1] [2] [3] .
We considered official death certification data for cancer of the stomach, colorectum, pancreas, lung, breast, uterus (cervix and corpus), prostate, as well as leukaemia and total neoplasms (malignant and benign) from the WHO database (WHOSIS) [7] . Using the matrices of certified deaths and resident populations, we computed age-specific death counts and rates for each 5-year age group (from 0-4 to 85þ years), sex and calendar year. We obtained age-standardized rates (world standard population) per 100 000 men and women, at all ages, using the direct method [8] . For lung cancer, we also computed rates for the 25-44, 45-64, 65-74 and 75þ year age groups for the EU.
We fit a logarithmic Poisson count data joinpoint regression model to the number of certified deaths in each 5-year age group in order to identify the most recent trend segment [9] . Thus, we applied a linear regression to mortality data for each 5-year age group over the most recent trend segment identified by the joinpoint model to compute the predicted agespecific certified numbers of deaths and the corresponding 95% prediction intervals (PIs). We estimated 95% PIs using a standard error accounting for the variability of the new observation [10] . Predicted standardized death rates with 95% PI were computed using the predicted age-specific deaths counts and the predicted population data from Eurostat [11]. Table 1 shows the total numbers of predicted cancer deaths (rounded to the nearest hundred) and rates with the corresponding 95% PIs for 2017, in the EU as a whole, for the neoplasms under study. Table 1 also includes the 2012 recorded data. Figure 1 shows bar plots of standardized death rates per 100 000 population for all cancers and the eight major cancer sites, in men and women in 2012 (dark grey, blue online), and the predicted values for 2017 (light grey, orange online) with corresponding 95% PIs.
Results
Overall, 1 373 500 EU deaths from cancer are predicted in 2017 (761 900 men and 611 600 women), when compared with 1 333 421 (745 281 men and 588 140 women) in 2012. The corresponding projected age-standardized rates for 2017 are 131.8/ 100 000 men and 84.5/100 000 women, compared with 143.5/ 100 000 men and 87.7/100 000 women recorded in 2012. Thus, an 8.2% fall in rates for men and a 3.6% fall in women are predicted between 2012 and 2017, while the absolute number of deaths is expected to increase by about 40 000 (þ3.0%).
In the EU, in 2017, lung cancer has the highest predicted agestandardized cancer mortality rate in both sexes. In men, the rate is 33.3/100 000, corresponding to 183 400 predicted deaths (24% of total male cancer deaths), and to a À10.7% fall in rates since 2012. In women, the predicted rate is 14.6/100 000, corresponding to 92 300 deaths (15% of total female cancer deaths) and a 5.1% rise in rates since 2012. Overall, lung cancer is predicted to cause 275 700 deaths in both sexes combined in 2017, corresponding to about 20% total cancer deaths.
Breast cancer projected rate in 2017 is 14.0/100 000 women, the second highest rate in women. However, the total number of deaths remains slightly higher for breast cancer (92 600) than for lung cancer. Between the ages of 45 and 74 years, more deaths from lung than breast cancer were predicted, while in young and elderly women breast cancer deaths remain more frequent. Colorectal cancer has predicted rates of 16.1 in men and 9.3/100 000 in women, corresponding to 97 100 deaths in men and 78 600 in women (about 13% of total cancer deaths in both sexes), and with, respectively, 5.3% and 6.7% falls in rates since 2012. Prostate cancer has the third highest projected rate (10.3/100 000 with a 6.9% fall since 2012), and accounts for about 10% of the total cancer deaths in men. Pancreatic cancer rates remain approximately stable in men, with a predicted rate of 7.9/100 000, while in women it rises to 5.6/100 000 (þ3.5%, compared with 2012). The total number of pancreatic cancer deaths (87 400) corresponds to about 6% of all cancer deaths. Cancers of the uterus, stomach and leukaemias represent 2, 4 and 3%, respectively, of total cancer deaths, and their falls since 2012 ranged between À16% (stomach in men) and À5% (uterus). Figure 2 gives trends in all ages total cancer mortality rates for men and women in the EU overall in quinquennia centred from 1972 to 2012, and the predicted rates for 2017 with PIs. In men, rates have been declining since the late 1980s, while in women rates declined during the whole studied period. However, recent falls were largest in men. Figure 3 shows mortality trends for each selected cancer site in the EU. Stomach cancer has the greatest proportional falls in mortality in both sexes. Lung cancer in men also shows considerable falls in mortality since 1990, as well as breast cancer in women. Pancreatic cancer in men shows an approximately stable trend over the last few years, while in women the rate rises steadily. Lung cancer in women shows a steady upward trend over the entire period. The supplementary appendix, available at Annals of Oncology online, provides country-specific data and analyses (supplementary Tables S1-S9 and Figure S1 , available at Annals of Oncology online). Table 2 gives all ages standardized mortality rates for lung cancer in the 2005-2009 quinquennium and in 2012, the predicted age standardized rate for 2017 and the percent difference between 2017 and 2012, in the six selected countries and in the EU as a whole. Moreover, for the EU, Table 2 shows specific figures for the age groups 25-44, 45-64, 65-74 and 75þ years.
In 2005-2009, overall lung cancer mortality rates among men ranged between 33.1 (the UK) and 62.0/100 000 men (Poland); all countries show downwards trends for 2017 between 25.7 (the UK) and 46.8/100 000 men (Poland). The overall decline in EU male, between 2012 and 2017, is 10.7%, and in all age groups the patterns are favourable, particularly in the 25-44 group (À48.5%). In women, the lowest rate for 2005-2009 was 6.3 in Spain, while the highest was 20.5/100 000 in the UK. Apart from the UK, all countries have unfavourable trends and predicted rates vary between 8.8 (Spain) and 19.1/100 000 women (the UK). Only young women show favourable patterns (À15.1%). Figure 4 shows joinpoint analysis for lung cancer agestandardized mortality rates for the EU, in both sexes, in the five studied age groups, along with predictions for 2017 and corresponding PIs. In men, all age groups display a downward trend since late 1980s/early 1990s. Women aged 25-44 years increased up to the late 1980s, and decline moderately thereafter. All other age groups show upwards trends. Figure 5 gives the estimated number of avoided cancer deaths for EU men and women between the top rate in 1988 and 2017 (light grey area, light green online). Over the 30 years period considered, 2 893 054 cancer deaths in men and 1 471 216 in women (for a total of 4 364 270) have been avoided. In 2017, 253 915 are predicted to be avoided in men and 107 780 in women, for a total of 361 695.
Discussion
EU mortality rates from all cancers combined and from most site-specific cancers are predicted to further fall to 2017, confirming the favourable trends in cancer mortality registered in Europe and other areas of the world over the last two decades [12, 13] . However, the fall in age-standardized rates is not reflected in the total number of deaths, since these are still expected to rise moderately, due to the continuous population's increase in size and ageing [14] . Despite a steady substantial decline in breast cancer mortality, the predicted fall in overall cancer mortality was smaller in women than in men (À4% versus À8%).
This essentially reflects the different trends in lung and other tobacco-related cancers between the two sexes [15] . In fact, lung cancer mortality in women is still rising, to reach an overall predicted rate of 14.6/100 000 in 2017, while it is decreasing by 11% in men. In the age group 25-44, predicted lung cancer rates in the EU are similar in men and women, reflecting the similar smoking patterns in the young generations of the two sexes over recent Figure 1 . Bar-plots of age-standardized (world population) death rates per 100 000 persons for the year 2012 (dark grey, blue online) and predicted rates for 2017 (light grey, orange online) with 95% prediction intervals (PIs) for total cancer and the eight major cancer sites in EU men and women.
decades [16] . This confirms that the impact of smoking on lung cancer is the same in men and women [17] . Despite the persisting unfavourable trends, female lung cancer rates remain consistently lower in the EU (except the UK and Poland) than in the USA [4] , and are unlikely to reach the high levels reached in the USA during the 1990s [18] . Only in the UK, where female lung cancer rates approached 20/100 000, trends appear to be levelling off, but the rise in other countries remains substantial, particularly in France and Spain, where smoking became common in women in the 1970s [19] . In general, all former non-market economy countries of central and eastern Europe have higher lung cancer rates in men, and the pattern of trends reported for Poland are reasonably representative of the area.
The other major neoplasm showing no favourable predictions is pancreatic cancer. Similar trends were registered for the USA [4, 20] . Tobacco is the major recognized risk factor for pancreatic cancer, but its attributable fraction is 15-25% in most populations [21, 22] . Thus, at least in men, some fall would have been expected, and indeed the recent trends were no longer rising. No real progress has been made in the screening, management and treatment of pancreatic cancer, and the increased prevalence of overweight, obesity and diabetes, mostly in northern Europe, may have unfavourably affected pancreatic cancer rates [23] .
The predicted downward trends for colorectal cancer and leukaemias in both sexes, as well as for cancers of the prostate [24] , breast and uterus [25] , likely reflect improved diagnoses, management and treatment of these neoplasms over the last three decades [26, 27] and are expected to continue in the near future.
Likewise, continuous falls are predicted for gastric cancer, probably due to the long term effects of the decreased prevalence of Helicobacter pylori infection in subsequent generations and across countries [28] . Still, major differences in gastric cancer mortality remain across Europe [29] , with rates about twice as high in Poland compared with the UK. Short term predictions of deaths and rates from major cancer sites provide a reasonable picture of current cancer burden in the EU, and have proven to be satisfactory robust for the EU and its major countries [3] . Still, none of the proposed models is able to estimate sudden fluctuations or major changes in slopes. Thus, as for any prediction, due caution is required for interpretation and inference.
In conclusion, cancer mortality rates are predicted to decline further in the EU, mainly in men following the decreased prevalence of smoking in subsequent generations in recent calendar decades. The persistent unfavourable trends in female lung cancer resulted in similar mortality rates in both sexes in the young, confirming the similar impact of tobacco on lung cancer in men and women. 
